225 filings
6-K
IPHA
Innate Pharma
15 Apr 24
Innate Pharma Announces Advancement Of Sanofi-Developed Nk Cell Engager Sar443579 / Iph6101 Progressing To Phase 2 For Blood Cancer Patients
6:02am
6-K
IPHA
Innate Pharma
15 Apr 24
Current report (foreign)
6:00am
6-K
IPHA
Innate Pharma
10 Apr 24
Innate Pharma Presents at AACR 2024 Preclinical Efficacy of its Pre-IND Drug Candidate IPH45, a Novel Nectin-4 Antibody Drug Conjugate
6:51am
20-F
2023 FY
IPHA
Innate Pharma
Annual report (foreign)
4 Apr 24
8:03am
6-K
IPHA
Innate Pharma
21 Mar 24
Summary of Consolidated Financial Statements and Notes
9:20am
6-K
IPHA
Innate Pharma
21 Mar 24
Innate Pharma reports Full Year 2023 Financial Results and Business Update
6:01am
6-K
IPHA
Innate Pharma
19 Mar 24
Innate Pharma Announces Its Participation To Upcoming Investor Conference
6:33am
6-K
IPHA
Innate Pharma
14 Mar 24
Innate Pharma Announces Conference Call And Webcast For Full Year 2023 Financial Results
7:00am
6-K
IPHA
Innate Pharma
6 Mar 24
Current report (foreign)
6:00am
6-K
IPHA
Innate Pharma
6 Mar 24
Current report (foreign)
6:00am
6-K
IPHA
Innate Pharma
21 Feb 24
Innate Pharma Announces Its Participation To Upcoming Investor Conference
6:00am
6-K
IPHA
Innate Pharma
6 Feb 24
Current report (foreign)
5:05pm
424B5
IPHA
Innate Pharma
6 Feb 24
Prospectus supplement for primary offering
5:00pm
EFFECT
IPHA
Innate Pharma
17 Jan 24
Notice of effectiveness
12:15am
6-K
IPHA
Innate Pharma
12 Jan 24
Innate Pharma S.a. 6-K
6:00am
CORRESP
IPHA
Innate Pharma
11 Jan 24
Correspondence with SEC
12:00am
6-K
IPHA
Innate Pharma
5 Jan 24
Innate Pharma S.a. 6-K
6:09am
6-K
IPHA
Innate Pharma
4 Jan 24
FDA lifts partial clinical hold on lacutamab clinical programFatal case related to disease progression and unrelated to the treatment
6:01am
6-K
IPHA
Innate Pharma
4 Jan 24
Innate Pharma 6-K
6:00am
UPLOAD
IPHA
Innate Pharma
26 Dec 23
Letter from SEC
12:00am